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Plasmodium falciparum malaria is brought about by the asexual stages of the parasite residing in human red blood cells (RBC).
Contact between the erythrocyte surface and the merozoite is the first step for successful invasion and proliferation of the
parasite. A number of different pathways utilised by the parasite to adhere and invade the host RBC have been characterized,
but the complete biology of this process remains elusive. We here report the identification of an open reading frame (ORF)
representing a hitherto unknown second exon of the Pf332 gene that encodes a cysteine-rich polypeptide with a high degree
of similarity to the Duffy-binding-like (DBL) domain of the erythrocyte-binding-ligand (EBL) family. The sequence of this DBL-
domain is conserved and expressed in all parasite clones/strains investigated. In addition, the expression level of Pf332
correlates with proliferation efficiency of the parasites in vitro. Antibodies raised against the DBL-domain are able to reduce
the invasion efficiency of different parasite clones/strains. Analysis of the DBL-domain revealed its ability to bind to uninfected
human RBC, and moreover demonstrated association with the iRBC surface. Thus, Pf332 is a molecule with a potential role to
support merozoite invasion. Due to the high level of conservation in sequence, the novel DBL-domain of Pf332 is of possible
importance for development of novel anti-malaria drugs and vaccines.
Citation: Moll K, Che ˆne A, Ribacke U, Kaneko O, Nilsson S, et al (2007) A Novel DBL-Domain of the P. falciparum 332 Molecule Possibly Involved in
Erythrocyte Adhesion. PLoS ONE 2(5): e477. doi:10.1371/journal.pone.0000477
INTRODUCTION
The invasion of RBC by a Plasmodium-merozoite is a cascade like
process involving adhesion, reorientation, junction-formation and
invagination. This procedure requires close interaction between
the parasite derived ligands and the host receptors on the RBC
surface (reviewed by Gaur et al. [1]). Interestingly, a majority of
Plasmodium falciparum merozoites released from ruptured schizonts
fail to invade new RBC in vitro. Further, P. falciparum purified
merozoites do not consistently infect RBC [2,3] while in contrast
isolated merozoites of both murine and primate malaria parasites
easily invade and proliferate within new RBC [3]. It has therefore
been speculated that parasite derived molecules adhering to the
merozoites are essential elements facilitating the invasion process
[4] or that a specific interaction between infected and uninfected
RBC prior to invasion may be necessary [5].
P. falciparum displays numerous parasite derived proteins on the
merozoite surface that fulfil important functions for the multipli-
cation of the parasite; the most important ones characterized so far
are the Merozoite surface protein 1 (MSP-1) and the Apical
membrane protein 1 (AMA-1), which are essential for the parasites
survival [6,7]. During the invasion process, the parasite forms
a tight junction with the RBC membrane involving several
proteins discharged from micronemes and rhoptries in the apical
part of the cell. Among these are the erythrocyte binding proteins
of the EBL-family located in the micronemes and the reticulocyte
binding like (RBL) proteins situated at the neck of the rhoptries,
which are expressed simultaneously by the merozoite. However, it
is probably the available receptor on the RBC surface that
determines which ligand the parasite employs for invasion [8].
EBA-175 was the first protein identified to be involved in the
junction formation between merozoite and RBC mediating
binding to the receptor glycophorin A (reviewed by Gaur et al.
[1]), followed by EBA-175 paralogues such as EBA-140 and EBA-
181 binding to glycophorin C or unknown receptors [9]. All
members of the EBA-family are featured by an N-terminal signal
sequence followed by a cysteine-rich motif with one or two Duffy-
binding like domains, a C-terminal cysteine-rich motif, a trans-
membrane (TM) domain and a short cytoplasmic tail. Parasite
mutants deficient in single members of the EBA-family do not
show a significantly reduced merozoite invasion rate, as demon-
strated by BAEBL/EBA-140 or JESEBL/EBA-180 knockout
clones that maintain a comparable RBC invasion rate as wild
type parasites [10,11]. However, single amino acid alterations in
the EBA-140 or EBA-181 sequences will lead to a change in
receptor specificity, while sequence polymorphism in EBA-175
does not change its receptor-binding specificity [10].
A recent study by Glushakova [12] illustrates that merozoites
invade RBC more efficiently when the iRBC are bound to
uninfected RBC prior to schizont rupture and merozoite release.
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RBC may likewise play an important role in the initial adhesion
process between merozoite and RBC [9]. A candidate molecule
mediating the interaction between late stage iRBC and RBC is the
polypeptide Pf332 (Antigen 332), which was first identified by
Mercereau-Puijalon [13,14]. Pf332 is highly glutamic acid rich
and contains long repetitive sequences in an internal region named
EB200, and a conserved tryptophan-rich domain (WRD) with
similarities to that of PfEMP-1, SURFIN, and PkSICAvar [4].
Antibodies targeting this region can block the adhesion of iRBC to
cells expressing CD36 and efficiently inhibit parasite invasion [15–
17]. However, antibodies to the glutamic-acid reach repeats cross-
react with several other P. falciparum proteins including Pf11-1,
RESA/Pf155 with similar repetitive sequences, and the specificity
of its inhibitory effect has therefore not been conclusive. Recent
studies suggest that Pf332 assembles together with a number of
different surface-related proteins such as the RIFINs and PfEMP1
in the erythrocyte-cytoplasm to be directed together to the
erythrocyte membrane [18] although the biological function of
Pf332 has remained unclear.
Here we propose that the open reading frame of Pf332 as
originally described [13,19] is in fact only the second exon of
a giant gene comprising two exons. We identified a previously
unrecognized Pf332 exon I, which is present in all parasite clones/
strains investigated and encodes an erythrocyte-binding DBL-
domain together with a transmembrane domain. Characterization
of both the native and in vitro expressed Pf332 DBL-domain
revealed its surface association and the ability to bind to human
RBC. Significantly, antibodies raised against this region were able
to reduce the invasion efficiency in vitro independent of geo-
graphical origin or receptor specificity of the P. falciparum clone/
strain. This suggests the conserved polypeptide encoded by exon I
of Pf332 exhibit a functional role during the RBC invasion process
and is therefore a potential novel candidate for a blood stage
vaccine.
RESULTS
The gene encoding Pf332 consists of two exons
separated by a short intron
During a survey to identify open reading frames (ORF) containing
domains able to bind to RBC, the ORF PF11_0506 was identified,
for which the adjacent ORF PF11_0507 encoding Pf332 started
only 280 bp after the predicted stop codon of PF11_0506. The
length of the intergenic region is very short compared to the mean
length in P. falciparum (1694 bp) [20] and was thus assumed to be
an intron rather than an intergenic region.
PCR amplification from gDNA and cDNA of the 3D7AH1
parasite clone was performed using a set of primers, where the
forward primer UP3 was located at the 39end of PF11_0506 and
the reverse primer UP4 at the 59end of PF11_0507 (Pf332). The
size of the RT-PCR products from cDNA was 350 bp (Fig. 1A),
whereas the size of the PCR products was 600 bp if gDNA of the
clones 3D7AH1 (Fig. 1B) or FCR3S1.2 (data not shown) were used
as a template. Comparison of the sequences of the PCR and RT-
PCR products revealed an intron sequence possessing typical ‘gt-
ag’ splicing sites at its ends.
To further confirm that the two transcripts of PF11_0506 and
PF11_0507 constitute a single mRNA, Northern blot hybridisa-
tions were performed with two different probes. Probe 1 was
located at 59-end of PF11_0506 (amplified with UP1 and UP2,
Fig 1A), while probe 2 covered the splicing sites (amplified with
UP3 and UP4, Fig 1A). RNA was purified from the 3D7AH1
clone at around 20 h post invasion (p.i.). The two probes
hybridised to a single transcript of a size considerably higher than
9.4 kb (Fig. 1C).
Combining these data, it can be concluded that the two ORFs
(PF11_0506 and PF11_0507) annotated in the 3D7 genome
database, as distinct genes are actually two exons of a single gene
encoding Pf332. The full size of the mRNA (3D7AH1) is 18282 bp
encoding a polypeptide of 6094 amino acids with a predicted
molecular weight of approximately 670 kDa.
The sequence of exon I of Pf332 is conserved in P.
falciparum
A single DNA fragment was amplified from 10 different P.
falciparum clones/strains originally isolated from various geo-
graphical locations and one Ugandan patient isolate. PCR
amplification was conducted with a pair of primers (UP1, UP5)
specific to the sequence of the 3D7AH1 clone (Fig. 1A and Fig.
S1). When digested with the restriction enzyme EcoR I (3
digestion sites are present in the 3D7AH1 sequence, data not
shown) the PCR products did not show any restriction fragment
length polymorphism (data not shown). In addition, the DNA
fragments of 11 parasite clones/strains (3D7AH1, NF54,
FCR3S1.2, TM284S2, Dd2, FCB-3, K1, R29, FCR3CSA, F32
and UAS22) encoded by exon I of the molecule were sequenced
and only four point mutations were found (in K1, 3D7AH1 and
Dd2; Table 1). In contrast, sequence polymorphism was mainly
reported in the repetitive region of exon II [14], as often seen in
molecules important during sporozoite and merozoite invasion
such as the repetitive regions of the circumsporozoite protein
(CSP) and the block two sequence of MSP-1.
Exon I of Pf332 encodes for a DBL-domain with high
similarity to the DBL-domains of the EBL-protein
family
BLASTP search and sequence alignment of the amino acid
sequence encoded by the ORF PF11_0506 revealed that the N-
terminal region (aa 1-250) possesses a domain homologous to the
DBL-domains of the EBL-family including e.g. the EBA-175 of P.
falciparum (Fig. S2) [21], although the overall protein structure of
Pf332 differs from this protein family. Pf332 does neither contain
a N-terminal segment (NTS) nor a signal leader sequence
upstream of the DBL-domain (Fig. 2). The DBL-domains of the
other EBL-family members are located further to the centre of the
molecule, downstream of a NTS of variable size. Further, all EBL-
family proteins presented an N-terminal signal peptide sequence.
Sequence comparison of the EBL-family proteins and the Pf332
showed that they share conserved cysteine residues and other
amino acid residues, which are of importance for maintaining the
structure of the molecule. Among 12 Cysteine-residues 5 are
conserved indicating the formation of at least two disulfide bonds
within the molecule (Fig. S2). The DBL-domain of Pf332 is more
similar to the F2 than to the F1 region of the EBA-175 protein
(Fig. 2); however, the absence of the WWXXXXXXXW sequence
motif commonly found in other EBL family members suggests
a distinct RBC-binding function for this domain.
Alignment with the EBL-family also reveals that Pf332 does
not have a C-terminal Cysteine-rich domain after the DBL-
domain. In contrast, Pf332 has a putative transmembrane region,
located close to the DBL-domain (aa 540–560) (Fig. 2). Four
membrane targeting motifs (RxLxE/Q) were found in the N-
terminal region (aa 77–81), in the middle (aa 2628–2632) and
close to the end (aa 4537–4541, 4922–4926) of the molecule,
indicating that Pf332 is a transmembrane protein with a similar
Pf332 and Erythrocyte Adhesion
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such as PfEMP1 [22,23].
Pf332 is expressed by all parasites studied
Microarray data illustrate that the transcription pattern of the
Pf332 gene is similar in all investigated parasite clones/strains
(HB3, 3D7, Dd2) [24,25]. This was confirmed by real-time
quantitative PCR analysis using RNA of three parasite clones/
strains (3D7AH1, FCR3S1.2, 7G8) collected every 4 hours from
8 h p.i. onwards. The primers used were specific to the 59 region
of the transcript. Transcription was normalized to seryl-tRNA
synthetase as an internal standard control. Results (Fig. 3A) clearly
showed that the gene encoding Pf332 is activated in all three
parasite clones/strains at approximately 16 h reaching maximal
transcription at 24 h p.i.. Although all parasite clones/strains
displayed the same transcription pattern, the level of transcription
varied considerably among the different clones/strains, with
Figure 1. Structural analysis of the gene encoding Pf332. A. Schematic structure of the Pf332 gene. The gene is composed of a 59 exon I
(PF11_0506) with a size of 1704 bp and a 39 exon II (PF11_0507), separated by a short intron of 236 bp. The 39-exon II is the gene fragment previously
referred to as the gene coding for the antigen Pf332. The location of the primers is indicated as arrows. B. PCR amplification from cDNA and gDNA
across the intron region of the Pf332 gene: Lane 1: PCR amplification with primers UP3 and UP4 from cDNA; lane 2: PCR amplification with the same
primer pair from gDNA. C. Northernblot with probes located at 59-end (UP1–UP2) and across the splicing site (UP3–UP4) of the Pf332 gene. Total RNA
from 3D7AH1 iRBC was resolved in an agarose gel (lanes 1 and 3). Lane 2 shows the hybridisation with the first probe (UP1–UP2); lane 4 shows the
hybridisation with the second probe (UP3–UP4) revealing a band of the same size as seen in the first hybridization.
doi:10.1371/journal.pone.0000477.g001
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3D7AH1 and 7G8 iRBC (Fig. 3A).
In addition, Pf332 expression was investigated in 3D7AH1,
FCR3S1.2 and 7G8 iRBC by immunofluorescence and Western
blot analysis with antibodies specific to the N-terminal region (a-
Pf332-DBL/nDBL) as compared to antibodies towards the
repetitive region (EB200) of the molecule and the human
monoclonal antibody m33G2 [16] (Fig. 3B, C and Fig. S3).
Expression of Pf332 starts immediately after initiation of
transcription [18] and reaches maximal levels at 36 h p.i..
Immunofluorescence with a-Pf332-DBL/nDBL sera visualized
that the protein is found within the parasitophorous vacuole at the
ring stage, while with maturation of the parasite it is transported
through the iRBC cytoplasm and directed towards the surface of
the host cell, as previously observed with sera against other regions
of the molecule (Fig. 3B).
Further, FCR3S1.2 iRBC displayed a higher expression rate of
Pf332 as compared to the two other strains (Fig. 3C) correspond-
ing to the transcription patterns visualized by quantitative PCR.
Interestingly, the parasite clone FCR3S1.2 has the fastest
multiplication rate among the three clones/strains investigated,
indicating that Pf332 might be a protein that supports the parasite
invasion process.
The DBL-domain of Pf332 is surface associated and
binds to human RBC in vitro
Immunofluorescence assays on live trophozoite iRBC (HB3,
FCR3S1.2) at 36 to 40 h p.i. using a serum raised against the
DBL-domain of Pf332 visualized that this domain is associated
with the surface of the iRBC (Fig. 4 A–D). In order to exclude that
the observed reactivity results from uptake of the antibody into the
iRBC, respectively leaky membranes as often observed in late
stage iRBC, IFA assays were in addition carried out with various
control proteins, which are parasite-derived, but not exposed on
the iRBC surface. Antibodies against the ATS-domain of PfEMP1,
PfEMP2 as well as an unrelated control protein did not show any
reactivity in these assays.
In order to investigate the function of the surface associated
DBL-domain, recombinant proteins (tagged with Gluthatione-S-
Transferase, GST) corresponding to either the DBL-domain
(Pf332-DBL) or nonDBL-domain (Pf332-nDBL) (Fig. 5A) of Pf332
were generated in E. coli. These recombinant domains were
assayed for their capacity to bind to human RBC. The Pf332-
DBL-domain bound to the surface of human RBC, while neither
the recombinant Pf332-nDBL-domain or an unrelated GST-
tagged control protein showed any affinity to human RBC (Fig 5B).
In additional experiments, receptors on the RBC surface were
modified with different enzymes. Treatment of RBC with
neuraminidase did not abolish the binding of the recombinant
Pf332-DBL-domain suggesting that the receptor of Pf332 is not
a glycophorin molecule, likewise treatment of the RBC with
trypsin or heparitinase did not influence the binding of the Pf332-
DBL-domain (data not shown).
To further illustrate the binding capacity of the DBL-domain,
CHO cells transiently expressing the DBL- or the nDBL-domain
on their surface were constructed and tested for their ability to
bind to human RBC. After transfection, 30–35% of the CHO cells
were positive for expression of the different domains. The cells
presenting the Pf332-DBL-domain were found to have RBC
attached to their surface, while the presence of either the Pf332-
Table 1. Amino acid substitutions in the region encoded by
exon I of Pf332
......................................................................
Parasite clone/
strain Position 69 Position 117 Position 329 Position 363
Dd2 Asn Thr Asn Thr
FCR3S1.2 Asn Thr Asn Met
FCB3 Asn Thr Asn Met
F32 Asn Thr Asn Met
K1 Cys Thr Asp Met
UAS22 Asn Thr Asn Met
TM284S2 Asn Thr Asn Met
3D7AH1 Asn Ala Asn Met
The amino acid residues of the consensus sequence of exon I of Pf332 are
shown for 8 different parasite strains/clones, substitutions found in these





























































Figure 2. Schematic illustration of the conserved structure of the erythrocyte-binding region of Pf332 and the EBL family. The N-terminal region
of the Pf332 encoded by exon I contains a Duffy-binding like domain homologous to the DBL-domain of the EBL-family. This domain of Pf332 is
located closer to the N-terminal part of the molecule and lacks a signal leading sequence as compared to the other EBL family members. It aligns with
the F2 region of EBA-175 of P. falciparum and the DBP of P. vivax. In addition, the carboxyl cysteine (c-cys)-rich domain present upstream of the
transmembrane domain in EBA-175 and DBP is not found in Pf332.
doi:10.1371/journal.pone.0000477.g002
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binding activity (Fig. 5C).
Antibodies against Pf332 decrease parasite invasion
efficiency
Invasion inhibition assays in which late stage parasites were
grown in the presence of a-Pf332-DBL/nDBL-antibodies
visualized the influence of Pf332 on parasite invasion. For the
three different parasite clones/strains FCR3S1.2, 3D7AH1 and
7G8, the antibodies showed an inhibition effect on invasion, with
reduction to around 60% observed at concentrations of 1 mg/ml
(Fig. 6), this effect was declining with decreasing concentrations
of the a-Pf332-DBL/nDBL-antibodies. Antibodies against MSP-
1 and AMA-1, known antigens involved in RBC invasion [6,7]
revealed a similar inhibition effect when used in the same
invasion inhibition assays. Although the influence of the a-
Pf332DBL/nDBL-antibodies was slightly lower, these antibodies
gave a similar pattern compared to the a-AMA-1/MSP-1
antibodies (Fig. 6), indicating a role of Pf332 during the
reinvasion process of the merozoites.
DISCUSSION
Successful attachment of the P. falciparum merozoite to the RBC
surface is the first important step in the process of invasion and
intracellular proliferation. Numerous in vitro studies have conclud-
ed that the cascade of the rapid invasion process, taking less than
20 seconds [26], is complex and involves a large number of
different molecules. Proteins such as the MSPs, AMA-1, EBL- and
Rh-family members located in the micronemes, the rhoptries or
on the merozoite surface have been shown to play a role in
attachment or invasion of the merozoite. However, many aspects
of this process remain to be elucidated. The molecule initiating the
contact between the merozoite and the RBC is not identified, and
the exact location of the invasion process within the human body is
still unknown. Furthermore, it is at present unclear as to which
molecular events underlie the loss of infectivity, which is observed
in merozoites isolated from in vitro grown P. falciparum parasites.
To shed additional light on the complex process of invasion we
have used the genome sequence of P. falciparum to identify proteins
Figure 3. Transcription and expression of Pf332 in different P.
falciparum clones/strains. A: The level of Pf332 mRNA transcription,
relative to the endogenous control seryl-tRNA synthetase, was
determined by real-time quantitative PCR. Normalized Pf332 levels
at different times p.i. are plotted for 3D7AH1 (N), FCR3S1.2 (#)a n d7 G 8
(.). Error bars represent the standard deviation of the quotient and *
denotes significantly higher levels of transcription in FCR3S1.2
(p,0.001, One Way ANOVA with Tukey test). The amount of Pf332
mRNA transcripts in FCR3S1.2 is around two fold higher than in
3D7AH1 and 7G8 at the time of maximal transcription. B: Upper panel:
B
Immunofluorescence staining with a-DBL/nDBL-domain antibodies of
Pf332. a-DBL/nDBL-domain antibodies (green) visualize at early
trophzoite stage (around 20 h p.i.) vesicles that carry Pf332 in the
cytosol of the iRBC; when the iRBC reaches late trophozoite/schizont
stage (40–47 h p.i.), Pf332 can be observed in association with the
iRBC membrane. Lower panel: Additional staining with the a-Pf332
monoclonal antibody m33G2. Staining with previously raised sera
against the Pf332 (m33G2, red) show that a-DBL/nDBL-domain
antibodies (green) co-localize with sera raised against the polypeptide
encoded by exon II of Pf332. Staining is shown for the parasite strain
7G8, DNA staining with Hoechst (blue); Scale bars=1 mm. C:
Immunoblot analysis confirmed that antibodies raised against the
DBL/nDBL-domain of Pf332 reacted with the same high molecular
weight polypeptide as the previously raised antibodies a-EB200 and
m33G2 (compare Fig. S3). This verifies that the sequence of the Pf332-
DBL/nDBL-domain is an additional exon of the same open
reading frame as the previously described Pf332. The total amount
of expressed Pf332 varies in between parasites, with FCR3S1.2
iRBC expressing the highest amount of Pf332. An a-glycophorin
antibody was used compare the amount of loaded material in the
different lanes. The bands corresponding to Pf332 are marked with an
asterix.
doi:10.1371/journal.pone.0000477.g003
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PF11_0506 that possesses a RBC-binding domain. Detailed
analysis of this gene fragment and the encoded protein has led
to several discoveries.
We have here revised the gene structure of Pf332. RT-PCR and
Northern blot clearly showed that the two predicted ORF
PF11_0506 and PF11_0507 are two exons of a single gene. This
conclusion was confirmed by Western blot analysis using three
different a-Pf332 antibodies to various regions of the polypeptide.
Exon II of Pf332 was initially identified from a gDNA expression
library containing only the region of repetitive sequence without
additional 59-RACE sequencing to identify the 59-end of the
transcript [15,27]. The existence of the additional upstream exon
in the gene of Pf332 has therefore previously been overlooked and
exon I (PF11_0506) was as a consequence annotated in the P.
falciparum genome as a separate gene encoding a hypothetical
protein. Our revision of the gene structure of Pf332 has paved the
way to dissect the biological function of Pf332, one of the largest
proteins found in P. falciparum parasites.
The first exon of Pf332 encodes a conserved erythrocyte-
binding domain homologous, but with a distinct sequence, to the
DBL-domains of the EBL-family. This sequence is, in contrast to
other erythrocyte-binding proteins, conserved among different P.
falciparum strains and clones. Proteins expressed by the Plasmodium
parasite often show sequence alterations in regions that are crucial
for immunity or undergo antigenic variation, in particular surface
related molecules, due to the constant pressure from the host
immune system. This also includes members of the EBL-family, as
for example the EBA-175, that are conserved only in function but
show variation within their sequence [28]. However, the
extracellular region of Pf332 displays a conserved sequence, which
might ensure the parasite’s ability to adhere to RBC independent
of the genetic background of the host. The capacity to bind
uninfected RBC to the schizont surface might act as a virulence
factor for the parasite, and greatly increase the invasion efficiency.
Due to the conservation of sequence in the DBL-domain this
virulence factor might be primarily of importance in non-immune
individuals without prior exposure to the parasite, rapid
acquisition of antibodies against this invariable domain in semi-
immune individuals could contribute substantially to protection
against high multiplication rates of the parasite and therewith
against severe disease.
A common feature of P. falciparum is that this parasite is able to
invade any human RBC, although the efficiency generally
depends on the carbohydrate moieties of the glycophorin on the
RBC surface. It can be hypothesized that the initial contact
between schizont and the RBC is the interaction of a conserved
receptor-ligand pair, a function that could be fulfilled by the DBL-
domain of Pf332 and an unknown receptor on the RBC surface,
while the invasion afterwards is dependant on molecules such as
MSP-1 and AMA-1. Numerous laboratory and patient isolates are
frequently found to form rosettes during late trophozoite and
schizont stage. This rosette formation is irrespective of the
‘‘classical rosetting’’ mediated by PfEMP1 taking place earlier in
the parasites lifecycle. Merozoites of these parasites invade more
efficiently uninfected RBC involved in these rosettes than into
unattached RBC (data not shown). The association of the DBL-
domain of Pf332 with the iRBC surface correlates with late stage
rosetting, indicating that Pf332 might facilitate invasion for
released merozoites through providing close proximity of new
host cells. Even though schizonts are often located in capillaries,
where the speed of blood flow is reduced due to sequestered and
agglutinated iRBC, the newly released merozoites would addi-
tionally benefit from a reduced distance towards new host cells.
Pf332 might in addition support the invasion process of merozoites
after rupture of the schizont. Accumulating amounts of Pf332
during schizont stage might loosely attach to the merozoites
surface assisting the parasite to more easily come in contact with
and to invade a new host cell after release from the schizont (Fig.
S4).
It has previously been suggested that the EB200 region of Pf332
with its degenerative repeats might function as an immunological
Figure 4. The Pf332 DBL-domain is iRBC surface associated. Immunofluorescence with antibodies against the DBL-domain visualizes the surface
association of the Pf332 DBL-domain as shown for HB3 iRBC (A+C) and FCR3S1.2 iRBC (B+D). A+B: Parasites are unstained; the RBC membrane is
indicated with a white line/arrow, the intracellular parasite with a grey line/arrow. C+D: Parasites are stained orange with Ethidium-bromide. Scale
bars=1 mm. E: Western blot with the same a-Pf332 DBL-domain antibody as used for the immunofluorescence assays; the antibody recognizes only
the molecule Pf332 and does not cross-react with any other proteins.
doi:10.1371/journal.pone.0000477.g004
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e477Figure 5. The DBL domain of Pf332 binds to human RBC. A: The protein Pf332 consists of a potentially extracellular region encoded by exon I and is
composed of a DBL- and nDBL-domain followed by a predicted transmembrane domain. The region of the molecule originally described as Pf332 is
encoded by a second exon and contains a Glutamic-acid rich part, which includes a Valin-rich area as well as the region EB200 build of numerous
repeats of a XXXEEXXEEXX motif (X=hydrophobic aa). B: The Pf332-DBL- and Pf332nDBL-region were expressed as two individual GST-fusion
proteins in E.coli. Binding assays, in which human RBC were incubated with the DBL-, nDBL- and an unrelated control protein were carried out.
Binding of the proteins was visualized by subjecting the RBC to immunoblotting, where the bound protein was detected with an a-GST antibody. The
DBL- but not the nDBL-domain or the unrelated control protein was able to bind to human RBC. C: Transient transfected CHO cells expressing either
the DBL- or nDBL-domain on their surface were tested for their ability to bind to human RBC. CHO cells were stained red with PHK26 and incubated
with RBC stained green with PKH67. CHO-cells expressing the DBL-domain avidly bound RBC, lower panel, while CHO cells expressing the nDBL-
region or MOCK-transfected cells did not show any binding towards RBC (middle and upper panel).
doi:10.1371/journal.pone.0000477.g005
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of the molecule [29]. In contrast to the DBL-domain, exon II
displays sequence polymorphism among different isolates possibly
attracting the host immune response and shielding the functional
N-terminal region of the molecule. Subsequently, the DBL-
domain of Pf332, although exposed in some way to the immune
system, is able to retain a conserved sequence mediating the
important first step of the process of RBC invasion. Still, the lack
of variation of the DBL-domain suggests that it is not overtly
exposed to the immunesystem as PfEMP1 or the RIFINs, but
concealed prior to exerting it function.
Quantitative differences in expression of Pf332 have been
reported from different P. falciparum strains in earlier studies [30].
Microarray data presented in the PlasmoDB (http://www.
plasmodb.org) show Pf332 to be transcribed in 3D7, Dd2 and
HB3 parasites with a higher transcription level in HB3 iRBC than
in the other strains. Interestingly, the chromosomal fragment
containing the gene of Pf332 is duplicated in the HB3 strain [31].
Here we confirm the transcription and expression of Pf332 by both
real-time quantitative PCR and semi-quantitative Western blot
analysis. In our quantitative PCR assays, the transcription level of
the gene was related to the transcription of seryl-tRNA synthetase,
a house-keeping gene which is constantly active during the whole
erythrocytic cycle of the parasite making it a suitable control for
time course studies of gene expression. RNA was collected every 4
hours from 8 h p.i. onwards and transcription of the Pf332 gene
was found to start at 16 h p.i. as described before [18,32]. While
the transcription pattern was similar in all parasite clones/strains,
the transcription level observed in FCR3S1.2 iRBC was more than
twice as high as in the other two strains (Fig. 3A), resulting in
a significantly higher expression of Pf332 as visualized in Western
blot assays (Fig. 3C) indicating a direct relation between Pf332
transcription and expression. Interestingly, among the parasite
clones/strains investigated, the FCR3S1.2 clone has the shortest
replication cycle (44–46 h instead of 48 h), and in addition an
approximately doubled multiplication rate compared to 3D7AH1
iRBC (data not shown) suggesting a potential benefit from
increased amounts of Pf332.
To date, the only parasite-derived protein on the iRBC surface
that is well characterized is the molecule PfEMP1. However,
PfEMP1 is mainly expressed in the earlier trophozoite stage and its
foremost function is to mediate adhesion of the iRBC to the
vascular endothelium. Pf332 is in contrast expressed at late
trophozoite and schizont stage and proposed to be involved in
binding of uninfected RBC. Immunofluorescence assays per-
formed in this study and earlier [18] show that Pf332 first
accumulates in the parasitophorous vacuole and is thereafter,
transported into the erythrocyte cytoplasm where it meets with
PfEMP1 and the RIFINs on their way towards the surface of the
iRBC. The Pf332 molecule contains four variant antigen-specific
translocation signal sequences (PEXEL motifs) [22,23] indicating
that this molecule is transported to the RBC surface. While Pf332
and PfEMP1 transiently co-localize in the late trophozoite stage,
their distribution pattern within the iRBC again differs during the
schizont stage reflecting functional differences of the two
molecules. Pf332 is presented later on the surface of the iRBC
than PfEMP1 and may participate in the sequestration process of
the iRBC in the microvasculature as previously suggested [16];
Figure 6. Antibodies directed against the DBL-domain of Pf332 inhibit parasite invasion. RBC infected with the parasite clones/strains FCR3S1.2,
3D7AH1 and 7G8 were cultivated in the presence of a-Pf332-DBL/nDBL-antibodies for 24 h allowing reinvasion of the parasites into new RBC. The
parasitemia was analysed by flow-cytometry and compared to a control cultivated in the presence of a serum raised against a non-related protein.
Parasites displayed a decreased invasion rate in the presence of a-Pf332-DBL/nDBL-antibodies. The effect of a-Pf332-DBL/nDBL-antibodies (light bars)
is slightly lower as compared to inhibition caused by antibodies against a hybrid protein of AMA1 and MSP1 (dark bars). Bars represent the mean of
three experiments; error bars indicate the standard deviation.
doi:10.1371/journal.pone.0000477.g006
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is further supported by our data obtained by quantitative PCR,
which illustrate that the Pf332 gene is activated at a later time
point during the erythrocytic life cycle than the var-genes. Even
though the DBL-domain of Pf332 is homologous to RBC invasion-
related proteins such as EBA-175 it clearly differs from these
microneme- and rhoptry-related molecules regarding the time of
transcription initiation (starts at around 38 h p.i. for these proteins,
PlasmoDB). Hence, Pf332 displays a distinct expression profile,
clearly distinguishing it from other P. falciparum surface molecules
pointing at a unique function of this molecule in the parasite life
cycle. Pf332 presents a novel type of invasion-related molecule
facilitating and supporting the invasion of future merozoites,
clearly different from other cytoadhesion-related proteins such as
PfEMP1 or merozoite invasion ligands (e.g. MSPs).
Despite the major interest in Pf332, its characterization has
been hampered by the fact that many of the a-Pf332 antibodies are
cross-reactive with other molecules, e.g. the Pf155/RESA also
containing regular repeats of glutamic acid [33]. Western blot
analysis of our antibodies raised against the DBL/nDBL-region of
the newly discovered exon I of Pf332 has revealed that these
antibodies are specifically reacting with the Pf332. They do not
recognize or cross-react with any other parasite antigens neither in
Western blot nor immunoflurescence assays carried out on
merozoites (Fig 3C, 4E and data not shown) supporting the
conclusion that the reduction of invasion efficiency of the a-Pf332-
DBL/nDBL antibody is specific. We could show that both
recombinant protein and antibodies to the DBL-domain of Pf332
reduce parasite invasion, while antibodies towards the PfEMP1 (a-
DBL1-domain) did not (Fig. 6 and data not shown). Comparing
the effect of our a-Pf332 antibodies with antibodies known to
target the process of invasion [6,7], a similar inhibitory effect is
observed, indicating that Pf332 might harbour a function during
the merozoite invasion process.
In conclusion, we have identified a molecule with a conserved
R B C - b i n d i n gD B L - d o m a i nt h a tp l a y sa ni m p o r t a n tr o l ei ni n v a s i o n
of the P. falciparum parasite. The protein is apparently essential for the
efficient proliferation of all P. falciparum parasites. This discovery can
have important implications in malaria vaccine development as well
as in designing new drugs to block parasite invasion.
MATERIALS AND METHODS
Bioinformatic analysis of the upstream sequence of
the Pf332 gene in the 3D7 genome
Analysis of the 3D7 parasite genome for sequences containing
RBC-binding motifs led to the identification of a hypothetical gene
(PF11_0506) located 281 bp upstream of the gene Pf332, which
potentially encodes a RBC-binding domain. PF11_0506 has one
ORF with a size of 1710 bp. The putative sequence of this
polypeptide was aligned with sequences of several EBL-family
proteins. The secondary structure and the cellular locations were
analysed with the Macvector program (GCG, UK).
Gene transcription and analysis
From total RNA purified with TRIZolH[34] first strand cDNA was
synthesized (GeneAmp RNA PCR Kit, Applied Biosystems, USA)
and further amplified with the primers UP3 (TAG TAC CAG
GAG TAT TAA CA) and UP4 (TTC CGT GTA TCT TCT
TCT TC) (Fig. 1). Northernblot was carried out with two anti-
sense digitonin-labelled RNA probes as described [4]. The RNA
probes were generated from two plasmids; plasmid 1 containing
a sequence amplified with primers UP1 (ATG TCT AAT ATA
AAT AAC AAA GAC TC) and UP2 (AGA ATT CAT CAC AAC
TCT CAT); plasmid 2 with a fragment amplified from cDNA with
primer UP3 and UP4 (Fig. 1).
Gene amplification and sequence analysis
To investigate the polymorphism of exon I, gDNA was purified
(from FCR3S1.2, 3D7AH1, NF54CSA, FCR3CSA, TM284, R29,
Dd2, K1, F32, FCB-3 and the Ugandan isolate UAS22, standard
methods) and PCR-amplification was carried out with primers
UP1 (ATG TCT AAT ATA AAT AAC AAA GAC TC) and UP5
(TAT TAC CTT ATA TAC CAA GAC C) (Fig. 1). Products were
cloned into the pCRII vector (Invitrogen USA) for sequencing.
Real-time quantitative PCR analysis of Pf332
transcription
RNA was harvested at 4 h p.i. intervals (RNeasyH Mini Kit, Qiagen,
Valencia, CA) and reverse transcriped (SuperScript III RNase H
reverse transcriptase, Invitrogen). For real-time quantitative PCR
reactions to monitor the relative expression of Pf332 to the
endogenous control seryl-tRNA synthetase we employed an MGB-
probe approach. Primers and probes were for Pf332: AAG AAG
ATG TGG GAT GTG TTC CA, CAT TTT CAT TAT CCA
ACC TTT CCA T and 6-FAM-CTA GGAG ACA GAA TTT
GA-MGB and for seryl-tRNA synthetase: TAT CAT CTC AAC AGG
TAT CTA CAT CTC CTA, TTT GAG AGT TAC ATG TGG
TAT CAT CTT TT and 6-FAM-AAA GAT ATC ATC ACA
GGC AGA T-MGB. Amplification reactions were done in
quadruplicates in MicroAmp 96 well plates in 20 ml, containing
TaqMan buffer with UNG (Applied Biosystems), 900 nM of each
forward and reverse primer, 200 nM of each probe and 2 ng of
template. 45 cycles (95uC for 15 sec and 60uCf o r1m i n )w e r e
performed in an ABI sequence detector 7500 (Applied Biosystems).
The detection threshold was set above the mean baseline value for
the first 6-15 cycles. Amplification efficiencies were verified by
performing amplifications using different concentrations of cDNA
for the target (Pf332) and reference (seryl-tRNA synthetase)a n dw e r e
sufficiently close to obviate the need for a correction factor. Results
were analyzed by the Relative Standard Curve Method where
a normalized target value was achieved by dividing the x ¯target with
the x ¯reference for each clone/strain and time point. The standard
deviationofthequotientwascalculatedaccordingtotheUserBulletin
2 (Applied Biosystems, http://www.appliedbiosystems.com). Results
werevisualizedaslog2transformedvaluesplottedusingSigmaPlot9.0
(SystatSoftwareInc.).StatisticallysignificantstraindifferencesinPf332
transcription were determined for each time point performing group
comparisons with One Way ANOVA and the Tukey test.
Generation of recombinant Pf332-DBL- and
nDBL-fusionproteins and binding to human RBC
GST- or his-fusion proteins were generated by cloning the ORF of
the DBL- and nDBL-domain into the pGEX-4T-1- (Amersham
Biosciences, Sweden, primer: Pf332-DBL: forward: GGA TCC
AGC AAC ATC AAC AAC AAG GA and reverse: CTC GAG
GTA CTT CTT CTC GAA CAC C; Pf332-nDBL: forward: GGA
TCC GCT AAT GAT AAT AAA TCA AAA CA and reverse:
CTC GAG TAT TTC CTG CAT TCA TTC C) or pQE60-vector
(Qiagen) (primer F-DBL: GCA TGC GAA GCA ACA TCA ACA
ACA AGG, R-DBL: GGA TCC GTA CTT CTT CTC GAA CAC
C) and recombinant proteins were expressed as described [35].
Recombinant protein (200 pmol) was incubated with 5 mlo f
washed RBC in RPMI for 2.5 h at 4uC, washed and bound
protein was visualized by Westernblot (a-GST mAb, dilution
1:5000, Sigma; a-mouse mAb-ALP, dilution 1:10000, Sigma). In
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for 1 h at 37uC), heparitinase (0.5 U in 50 mM Tris for 1 h at
37uC) or trypsin (100 mg/ml in PBS for 1 h at 37uC) in a 20 ml
scale before the binding assays.
Surface-expression of the Pf332-DBL- and
Pf332-nDBL-domain on CHO-cells and binding to
human RBC
The Pf332-DBL- (optimized for expression in mammalian cells,
GeneArt, Germany) and Pf332-nDBL-domain were cloned into
the pDisplay vector (Invitrogen). Transfection of CHO-cells was
performed with the FuGENE 6 transfection reagent (Roche
Applied Science, Switzerland) and expression of the domains on
the cell surface was confirmed by immunofluorescence 48 h later
(a-HA-antibody, Invitrogen; Alexa-labelled-a-mouse-antibody,
Molecular probe, USA).
For detection of RBC-binding transfected CHO-cells were
detached, and stained with PKH67 (green); human RBC were in
parallel stained with PKH26 (red). CHO-cells were incubated with
RBC at a ratio of 1:5 for 1 h at RT and the rosette formation was
afterwards analysed by fluorescence microscopy.
Generation of specific antibodies against the region
encoded by exon I of Pf332
The region encoded by exon I of Pf332 (aa 1–533) was cloned into
the Semliki forest virus vector SFV3.spider (primer: 332-F-SFV
(CCC GGG ATG TCT AAT ATA AAT AAC AAA GAC and 332-
RII-SFV (CCC GGG ATA ATT TCC TGC ATT CAT TCC
ATC) and virus particles generated as described before [36].
Rabbits (New Zeeland white) or rats were immunized (three times
5610
8 particles/animal, once 500 mg protein/animal, respectively
four times 100 mg protein/animal).
Immunodetection of Pf332 in Westernblot and
immunofluorescence on fixed and live iRBC
Trophozoite iRBC were purified [37,38], lysed in SDS-loading
buffer, analyzed by 6% SDS-PAGE (2610
6 cells/lane) and
subjected to various a-Pf332 sera. Visualization was performed
with an a-rabbit Ig- (1:5000, Amersham) or an a-human Ig-HRP-
conjugate (1:1500, Amersham).
For immunofluorescence assays, monolayers of iRBC were pre-
pared as described before [18]. Monolayers were incubated 30 min
with the a-Pf332-DBL/nDBL antibody (1:800)or pre-immune serum
(1:800), washed three times in PBS, and incubated 30 min with
a secondary antibody (a-rabbit-Alexa, Molecular Probes, 1:100).
For live IFA-assays, monolayers were prepared on adhesive slides
(Marienfeld Glassware) according to the manufacturer’s protocol.
Negativelychargedcellsareboundtotheseslidesbasedonelectrostatic
adhesionwithoutadditionalfixationstepsallowingtheinvestigationof
live late-stage iRBC. The cells were incubated with the a-Pf332-DBL
antibody (1:50), pre-immune serum (1:50), a-PfEMP2 (1:50) or serum
to an unrelated control protein (1:50),washed three times in PBS, and
incubated with a secondary antibody (a-rat-Alexa, Molecular Probes,
dilution 1:300) and counterstained with Ethidium-bromide. All
incubations were carried out at room temperature in a humid
chamber. Slides were analyzed with a 1006oil immersion lens in
a Nikon Optiphot 2 UV microscope.
Invasion inhibition assay
IRBC of various parasite clones/strains at trophozoite stage were
adjusted to a parasitemia of 1% and a hematocrit of 2.5%, mixed
with the purified IgG fraction of an a-Pf332-DBL/nDBL-, a-GST-
or a- AMA1/MSP1-serum [39] in final concentrations of 1, 0.5
and 0.25 mg/ml (in duplicates) and cultivated in 96-well plates
until reinvasion of merozoites was completed. IRBC were stained
with Acridine Orange and counted (50,000 events) by flow
cytometry. Experiments were repeated three times and the effect
was determined by relating the observed parasitemia in the
presence of a-Pf332-DBL/nDBL- or a-AMA1/MSP1-antibodies
to a-GST antibodies (negative control).
SUPPORTING INFORMATION
Figure S1 The sequence of the exon I of Pf332 is conserved
among various parasite clones/strains. PCR amplification of the
exon I region of the Pf332 gene from gDNA of various parasites
showed a single product of 1710 bp (primer UP1 and UP5;
compare Fig. 1A) from 10 different P. falciparum clones/strains
and one Ugandan isolate. Enzymatic treatment of the amplified
fragments with EcoR I illustrated that there was only one sequence
in each amplicon. All amplified products were cloned and
sequenced and only 4 mutations were identified among the 11
sequences (compare table 1).
Found at: doi:10.1371/journal.pone.0000477.s001 (0.24 MB TIF)
Figure S2 Alignment of the amino acid sequence of the EBL-
family members. The sequence of Pf332 encoded by exon I shares
numerous amino acid residues (highlighted with stars) that are
conserved among the erythrocyte-binding proteins of different
Plasmodium-species such as the sequences of the DBL-domain of
the P. vivax Duffy binding protein (DBP), P. knowlesi DBP, P.
cynomolgi DBP, BAEBL/EBA-140, JESEBL/EBA-181 and EBA-
175 of P. falciparum
Found at: doi:10.1371/journal.pone.0000477.s002 (0.31 MB TIF)
Figure S3 Immunoblot analysis of the molecule Pf332. Anti-
bodies towards the repetitive region EB200 and the monoclonal
antibody m33G2 have previously been used to characterize the
molecule Pf332. These antibodies react with the same high
molecular weight polypeptide as were recognized by antibodies
raised towards the DBL/nDBL-region of Pf332. The same
recognition pattern could be observed in all parasite strains/
clones (3D7AH1, 7G8, FCR3S1.2) investigated. The band
corresponding to Pf332 is marked with an asterix.
Found at: doi:10.1371/journal.pone.0000477.s003 (0.88 MB TIF)
Figure S4 Schematic model of the role of the DBL-domain of
Pf332 during merozoite invasion. A: The DBL-domain of Pf332 is
exposed on the late stage iRBC surface and mediates binding to
uninfected RBC causing a ‘‘late resetting’’ phenotype. This process
provides close proximity of new host cells and facilitates invasion of
the released merozoites into new RBC. B: The molecule Pf332 is
surface associated. It accumulates during schizont stage and
attaches loosely to the merozoites surface assisting the parasite to
more easily come in contact with and to invade a new host cell
after release from the schizont
Found at: doi:10.1371/journal.pone.0000477.s004 (0.32 MB TIF)
ACKNOWLEDGMENTS
Author Contributions
Conceived and designed the experiments: QC UR KM OK. Performed
the experiments: UR AC KM GW MH SN. Analyzed the data: QC UR
AC KM OK. Contributed reagents/materials/analysis tools: MW WP KB.
Wrote the paper: QC KM.
Pf332 and Erythrocyte Adhesion
PLoS ONE | www.plosone.org 10 May 2007 | Issue 5 | e477REFERENCES
1. Gaur D, Mayer DC, Miller LH (2004) Parasite ligand-host receptor interactions
during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol 34:
1413–1429.
2. Perkins M (1981) Inhibitory effects of erythrocyte membrane proteins on the in
vitro invasion of the human malarial parasite (Plasmodium falciparum) into its host
cell. J Cell Biol 90: 563–567.
3. Chitnis CE, Blackman MJ (2000) Host cell invasion by malaria parasites.
Parasitol Today 16: 411–415.
4. Winter G, Kawai S, Haeggstrom M, Kaneko O, von Euler A, et al. (2005)
SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites
and infected erythrocytes. J Exp Med 201: 1853–1863.
5. Wahlgren M, Carlson J, Udomsangpetch R, Perlmann P (1989) Why do
Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte ro-
settes? Parasitol Today 5: 183–185.
6. O’Donnell RA, Saul A, Cowman AF, Crabb BS (2000) Functional conservation
of the malaria vaccine antigen MSP-119across distantly related Plasmodium
species. Nat Med 6: 91–95.
7. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical
membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium
species. Mol Microbiol 38: 706–718.
8. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF (2005) Invasion by P.
falciparum merozoites suggests a hierarchy of molecular interactions. PLoS
Pathog 1: e37.
9. Cowman AF, Crabb BS (2006) Invasion of red blood cells by malaria parasites.
Cell 124: 755–766.
10. Maier AG, Duraisingh MT, Reeder JC, Patel SS, Kazura JW, et al. (2003)
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection
for Gerbich negativity in human populations. Nat Med 9: 87–92.
11. Gilberger TW, Thompson JK, Triglia T, Good RT, Duraisingh MT, et al.
(2003) A novel erythrocyte binding antigen-175 paralogue from Plasmodium
falciparum defines a new trypsin-resistant receptor on human erythrocytes. J Biol
Chem 278: 14480–14486.
12. Glushakova S, Yin D, Li T, Zimmerberg J (2005) Membrane transformation
during malaria parasite release from human red blood cells. Curr Biol 15:
1645–1650.
13. Mercereau-Puijalon O, Langsley G, Mattei D (1987) Presence of cross-reacting
determinants on several blood stage antigens of Plasmodium falciparum.I n :
‘‘Molecular Strategies of Parasitic Invasion’’. N Agabian, H Goodman, N
Nogueira, eds. UCLA Symposium 42 A R Liss, New York. pp 343–354.
14. Mercereau-Puijalon O, Jacquemot C, Sarthou JL (1991) A study of the genomic
diversity of Plasmodium falciparum in Senegal. 1. Typing by Southern blot analysis.
Acta Trop 49: 281–292.
15. Mattei D, Scherf A (1992) The Pf332 gene of Plasmodium falciparum codes for
a giant protein that is translocated from the parasite to the membrane of infected
erythrocytes. Gene 110: 71–79.
16. Udomsangpetch R, Aikawa M, Berzins K, Wahlgren M, Perlmann P (1989)
Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its
inhibition by a human monoclonal antibody. Nature 338: 763–765.
17. Wahlin B, Sjolander A, Ahlborg N, Udomsangpetch R, Scherf A, et al. (1992)
Involvement of Pf155/RESA and cross-reactive antigens in Plasmodium falciparum
merozoite invasion in vitro. Infect & Immun 60: 443–449.
18. Haeggstrom M, Kironde F, Berzins K, Chen Q, Wahlgren M, et al. (2004)
Common trafficking pathway for variant antigens destined for the surface of the
Plasmodium falciparum-infected erythrocyte. Mol Biochem Parasitol 133: 1–14.
19. Mattei D, Berzins K, Wahlgren M, Udomsangpetch R, Perlmann P, et al. (1989)
Cross-reactive antigenic determinants present on different Plasmodium falciparum
blood-stage antigens. Parasite Immunol 11: 15–29.
20. Gardner MJ, Shallom SJ, Carlton JM, Salzberg SL, Nene V, et al. (2002)
Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14. Nature 419:
531–534.
21. Howell DP, Samudrala R, Smith JD (2006) Disguising itself–insights into
Plasmodium falciparum binding and immune evasion from the DBL crystal
structure. Mol Biochem Parasitol 148: 1–9.
22. Marti M, Good RT, Rug M, Knuepfer E, Cowman AF (2004) Targeting
malaria virulence and remodeling proteins to the host erythrocyte. Science 306:
1930–1933.
23. Hiller NL, Bhattacharjee S, van Ooij C, Liolios K, Harrison T, et al. (2004) A
host-targeting signal in virulence proteins reveals a secretome in malarial
infection. Science 306: 1934–1937.
24. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, et al. (2003) The
transcriptome of the intraerythrocytic developmental cycle of Plasmodium
falciparum. Plos Biol 1: E5.
25. Llinas M, Bozdech Z, Wong ED, Adai AT, DeRisi JL (2006) Comparative whole
genome transcriptome analysis of three Plasmodium falciparum strains. Nucleic
Acids Res 34: 1166–1173.
26. Pasvol G (2003) How many pathways for invasion of the red blood cell by the
malaria parasite? Trends Parasitol 19: 430–432.
27. Mattei D, Scherf A (1992) The Pf332 gene codes for a megadalton protein of
Plasmodium falciparum asexual blood stages. Mem I Oswaldo Cruz 87 Suppl 3:
163–168.
28. Liang H, Sim BK (1997) Conservation of structure and function of the
erythrocyte-binding domain of Plasmodium falciparum EBA-175. Mol Biochem
Parasitol 84: 241–245.
29. Anders RF (1986) Multiple cross-reactivities amongst antigens of Plasmodium
falciparum impair the development of protective immunity against malaria.
Parasite Immunol 8: 529–539.
30. Udomsangpetch R, Carlsson J, Wahlin B, Holmquist G, Ozaki LS, et al. (1989)
Reactivity of the human monoclonal antibody 33G2 with repeated sequences of
three distinct Plasmodium falciparum antigens. J Immunol 142: 3620–3626.
31. Hinterberg K, Mattei D, Wellems TE, Scherf A (1994) Interchromosomal
exchange of a large subtelomeric segment in a Plasmodium falciparum cross.
EMBO J 13: 4174–4180.
32. Hinterberg K, Scherf A, Gysin J, Toyoshima T, Aikawa M, et al. (1994)
Plasmodium falciparum: the Pf332 antigen is secreted from the parasite by
a brefeldin A-dependent pathway and is translocated to the erythrocyte
membrane via the Maurer’s clefts. Exp Parasitol 79: 279–291.
33. Ahlborg N, Berzins K, Perlmann P (1991) Definition of the epitope recognized
by the Plasmodium falciparum-reactive human monoclonal antibody 33G2. Mol
Biochem Parasitol 46: 89–95.
34. Ljungstro ¨m I, Perlmann H, Schlichtherle M, Scherf A, Wahlgren M (2004)
Methods in Malaria Research, 4th ed MR4/ATCC Manassas: Virginia, http://
www.malaria.atcc.org/MR4_Protocols.html.
35. Flick K, Ahuja S, Chene A, Bejarano MT, Chen Q (2004) Optimized expression
of Plasmodium falciparum erythrocyte membrane protein 1 domains in Escherichia
coli. Malaria J 3: 50.
36. Chen Q, Pettersson F, Vogt AM, Schmidt B, Ahuja S, et al. (2004)
Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt
rosettes and protect against the sequestration of Plasmodium falciparum-infected
erythrocytes. Vaccine 22: 2701–2712.
37. Uhlemann R, Staalsoe T, Klinkert M, Hviid L (2000) Analysis of Plasmodium
falciparum-infected red blood cells. MACS&more 4: 7–8.
38. Pettersson F, Vogt AM, Jonsson C, Mok BW, Shamaei-Tousi A, et al. (2005)
Whole-body imaging of sequestration of Plasmodium falciparum in the rat. Infect
Immun 73: 7736–7746.
39. Pan W, Huang D, Zhang Q, Qu L, Zhang D, et al. (2004) Fusion of two malaria
vaccine candidate antigens enhances product yield, immunogenicity, and
antibody-mediated inhibition of parasite growth in vitro. J Immunol 172:
6167–6174.
Pf332 and Erythrocyte Adhesion
PLoS ONE | www.plosone.org 11 May 2007 | Issue 5 | e477